Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
16 studies found for:    River-PCI
Show Display Options
Rank Status Study
1 Active, not recruiting Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)
Conditions: Coronary Artery Disease;   Angina Pectoris
Interventions: Drug: Ranolazine;   Drug: Placebo
2 Completed Brain Irradiation in Treating Patients With Limited-Stage Small Cell Lung Cancer
Condition: Lung Cancer
Intervention: Radiation: Prophylactic Cranial Irradiation (PCI)
3 Completed The SEPIA-PCI Trial: Otamixaban in Comparison to Heparin in Subjects Undergoing Non-Urgent Percutaneous Coronary Intervention
Condition: Angioplasty, Transluminal, Percutaneous Coronary
Interventions: Drug: Otamixaban (XRP0673);   Drug: Unfractionated Heparin;   Procedure: Percutaneous Coronary Intervention
4 Terminated Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)
Conditions: Acute Coronary Syndrome;   Myocardial Infarction;   Coronary Artery Disease;   Percutaneous Coronary Intervention
Interventions: Drug: CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin;   Drug: Plavix (clopidogrel 75 mg) and aspirin
5 Recruiting Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Anemia;   Fever, Sweats, and Hot Flashes;   Stage I Chronic Lymphocytic Leukemia;   Stage I Small Lymphocytic Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Small Lymphocytic Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Small Lymphocytic Lymphoma;   Weight Changes
Interventions: Drug: ibrutinib;   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Biological: rituximab;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
6 Recruiting Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
Conditions: Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
Interventions: Drug: ibrutinib;   Biological: rituximab;   Drug: bendamustine hydrochloride;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
7 Completed Randomized Comparison Angioplasty Outcomes at Hospitals With and Without On-site Cardiac Surgery
Conditions: Coronary Arteriosclerosis;   Angina Pectoris
Intervention: Other: Percutaneous coronary intervention (PCI)
8 Unknown  Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer
Conditions: Chemotherapeutic Agent Toxicity;   Fallopian Tube Cancer;   Neurotoxicity;   Ovarian Cancer;   Pain;   Peripheral Neuropathy;   Primary Peritoneal Cavity Cancer
Interventions: Drug: carboplatin;   Drug: glutathione;   Drug: paclitaxel;   Other: placebo
9 Recruiting Radiation Therapy in Treating Patients With Extensive Stage Small Cell Lung Cancer
Condition: Lung Cancer
Interventions: Radiation: prophylactic cranial irradiation;   Radiation: selective external radiation therapy
10 Completed Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy
Condition: Acute Coronary Syndrome
Interventions: Drug: Otamixaban (XRP0673);   Drug: Otamixaban matching placebo;   Drug: Unfractionated Heparin;   Drug: Unfractionated Heparin matching placebo;   Drug: Eptifibatide;   Drug: Eptifibatide matching placebo
11 Completed The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial
Condition: Acute Coronary Syndrome
Interventions: Drug: Darapladib 160 mg;   Drug: Placebo;   Other: Standard Therapy
12 Recruiting Registry of Non-primary Angioplasty at Hospitals Without Surgery On-site
Conditions: Coronary Artery Disease;   Heart Attack;   Angina
Intervention:
13 Active, not recruiting PREDETERMINE Cohort Study
Conditions: Coronary Artery Disease;   Left Ventricular Dysfunction;   Sudden Cardiac Death
Intervention:
14 Recruiting Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Condition: Chronic Lymphocytic Leukemia
Intervention:
15 Recruiting Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion
Condition: Coronary Artery Disease
Intervention:
16 Recruiting Connect® MM- The Multiple Myeloma Disease Registry
Condition: Multiple Myeloma
Intervention:

Indicates status has not been verified in more than two years